Logo image of EWTX

EDGEWISE THERAPEUTICS INC (EWTX) Stock Fundamental Analysis

NASDAQ:EWTX - Nasdaq - US28036F1057 - Common Stock - Currency: USD

16.4  +0.94 (+6.08%)

After market: 16.4 0 (0%)

Fundamental Rating

3

Overall EWTX gets a fundamental rating of 3 out of 10. We evaluated EWTX against 198 industry peers in the Pharmaceuticals industry. EWTX has a great financial health rating, but its profitability evaluates not so good. EWTX has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

EWTX had negative earnings in the past year.
In the past year EWTX has reported a negative cash flow from operations.
EWTX had negative earnings in each of the past 5 years.
In the past 5 years EWTX always reported negative operating cash flow.
EWTX Yearly Net Income VS EBIT VS OCF VS FCFEWTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -50M -100M -150M

1.2 Ratios

EWTX has a Return On Assets (-27.49%) which is in line with its industry peers.
EWTX's Return On Equity of -29.14% is fine compared to the rest of the industry. EWTX outperforms 62.12% of its industry peers.
Industry RankSector Rank
ROA -27.49%
ROE -29.14%
ROIC N/A
ROA(3y)-25.12%
ROA(5y)-20.69%
ROE(3y)-26.69%
ROE(5y)-21.83%
ROIC(3y)N/A
ROIC(5y)N/A
EWTX Yearly ROA, ROE, ROICEWTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -10 -20 -30 -40

1.3 Margins

EWTX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
EWTX Yearly Profit, Operating, Gross MarginsEWTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024

More info and screens

8

2. Health

2.1 Basic Checks

EWTX has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, EWTX has more shares outstanding
There is no outstanding debt for EWTX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
EWTX Yearly Shares OutstandingEWTX Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
EWTX Yearly Total Debt VS Total AssetsEWTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

An Altman-Z score of 34.16 indicates that EWTX is not in any danger for bankruptcy at the moment.
EWTX's Altman-Z score of 34.16 is amongst the best of the industry. EWTX outperforms 96.46% of its industry peers.
There is no outstanding debt for EWTX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 34.16
ROIC/WACCN/A
WACCN/A
EWTX Yearly LT Debt VS Equity VS FCFEWTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 100M -100M 200M 300M 400M

2.3 Liquidity

A Current Ratio of 19.93 indicates that EWTX has no problem at all paying its short term obligations.
EWTX has a better Current ratio (19.93) than 92.42% of its industry peers.
EWTX has a Quick Ratio of 19.93. This indicates that EWTX is financially healthy and has no problem in meeting its short term obligations.
EWTX has a Quick ratio of 19.93. This is amongst the best in the industry. EWTX outperforms 92.42% of its industry peers.
Industry RankSector Rank
Current Ratio 19.93
Quick Ratio 19.93
EWTX Yearly Current Assets VS Current LiabilitesEWTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 8.23% over the past year.
EPS 1Y (TTM)8.23%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%10.64%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, EWTX will show a very strong growth in Earnings Per Share. The EPS will grow by 22.91% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-31.12%
EPS Next 2Y-20.12%
EPS Next 3Y-13.45%
EPS Next 5Y22.91%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EWTX Yearly Revenue VS EstimatesEWTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2026 2027 2028 2029 2030 2031 2032 500M 1B 1.5B 2B
EWTX Yearly EPS VS EstimatesEWTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 4 6 8

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for EWTX. In the last year negative earnings were reported.
Also next year EWTX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
EWTX Price Earnings VS Forward Price EarningsEWTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
EWTX Per share dataEWTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4

4.3 Compensation for Growth

A cheap valuation may be justified as EWTX's earnings are expected to decrease with -13.45% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-20.12%
EPS Next 3Y-13.45%

More info and screens

0

5. Dividend

5.1 Amount

EWTX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

EDGEWISE THERAPEUTICS INC

NASDAQ:EWTX (4/30/2025, 8:02:20 PM)

After market: 16.4 0 (0%)

16.4

+0.94 (+6.08%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)03-03 2025-03-03/bmo
Earnings (Next)05-08 2025-05-08/bmo
Inst Owners86.08%
Inst Owner Change0.06%
Ins Owners0.53%
Ins Owner Change0.01%
Market Cap1.72B
Analysts82.67
Price Target41.57 (153.48%)
Short Float %15.72%
Short Ratio6.47
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)3.08%
Min EPS beat(2)1.18%
Max EPS beat(2)4.98%
EPS beat(4)4
Avg EPS beat(4)6.7%
Min EPS beat(4)1.18%
Max EPS beat(4)17.47%
EPS beat(8)6
Avg EPS beat(8)4.67%
EPS beat(12)9
Avg EPS beat(12)4.22%
EPS beat(16)10
Avg EPS beat(16)1.9%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-14.08%
PT rev (3m)-17.56%
EPS NQ rev (1m)-0.81%
EPS NQ rev (3m)-13.49%
EPS NY rev (1m)3.36%
EPS NY rev (3m)-1.93%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 3.74
P/tB 3.74
EV/EBITDA N/A
EPS(TTM)-1.45
EYN/A
EPS(NY)-1.9
Fwd EYN/A
FCF(TTM)-1.05
FCFYN/A
OCF(TTM)-1.04
OCFYN/A
SpS0
BVpS4.38
TBVpS4.38
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -27.49%
ROE -29.14%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-25.12%
ROA(5y)-20.69%
ROE(3y)-26.69%
ROE(5y)-21.83%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 57.29%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 19.93
Quick Ratio 19.93
Altman-Z 34.16
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)629.66%
Cap/Depr(5y)448.48%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)8.23%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%10.64%
EPS Next Y-31.12%
EPS Next 2Y-20.12%
EPS Next 3Y-13.45%
EPS Next 5Y22.91%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-38.9%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-26.25%
EBIT Next 3Y-16.81%
EBIT Next 5Y36.11%
FCF growth 1Y-12.95%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-18.58%
OCF growth 3YN/A
OCF growth 5YN/A